Literature DB >> 11072204

Cervical cancer screening in Denmark.

J Bigaard1, J Hariri, E Lynge.   

Abstract

Denmark is divided into 15 counties and it is up to regional politicians and the health authority in each county to organise the cervical screening programmes. The National Board of Health issued national guidelines and recommendations for the cervical cancer screening back in 1986, and these guidelines are now, in 1998, almost fully implemented. In this study, a literature review on cervical cancer screening in Denmark, review of local guidelines, personal interviews with pathologists and collection of information about the education of cytotechnologists in Denmark was carried out. In Denmark in 1997 90% of women aged 23-59 years and 46% of women aged 60-74 years were covered by organised screening. A total of 650000 smears were taken annually. This figure corresponds to screening of all Danish women aged 25-59 years on average, every second year. The national recommendation is screening every third year. Thus, as the incidence of cervical cancer in Denmark is decreasing, we could probably move towards a longer screening interval. However, before the Danish recommendations are changed, more detailed data on the actual performances of screening programmes are warranted.

Entities:  

Mesh:

Year:  2000        PMID: 11072204     DOI: 10.1016/s0959-8049(00)00309-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

Review 1.  Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India.

Authors:  Sudha Sivaram; Gautam Majumdar; Douglas Perin; Ashrafun Nessa; Mireille Broeders; Elsebeth Lynge; Mona Saraiya; Nereo Segnan; Rengaswamy Sankaranarayanan; Preetha Rajaraman; Edward Trimble; Stephen Taplin; G K Rath; Ravi Mehrotra
Journal:  Lancet Oncol       Date:  2018-02       Impact factor: 41.316

2.  Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis--an observational cohort study.

Authors:  Lars Skov Dalgaard; Ulrik Fassel; Lars Jørgen Østergaard; Bente Jespersen; Ole Schmeltz Søgaard; Søren Jensen-Fangel
Journal:  BMC Nephrol       Date:  2013-07-08       Impact factor: 2.388

3.  An adverse event in a well-established cervical cancer screening program: an observational study of 19,000 females unsubscribed to the program.

Authors:  Mette Bach Larsen; Hans Svanholm; Berit Andersen
Journal:  J Healthc Leadersh       Date:  2016-10-27

Review 4.  Vaginal drug delivery for the localised treatment of cervical cancer.

Authors:  Ian Major; Christopher McConville
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

5.  Non-Adherence To Childhood HPV Vaccination Is Associated With Non-Participation In Cervical Cancer Screening - A Nationwide Danish Register-Based Cohort Study.

Authors:  Sara Badre-Esfahani; Mette Bach Larsen; Lene Seibæk; Lone Kjeld Petersen; Jan Blaakær; Henrik Støvring; Berit Andersen
Journal:  Clin Epidemiol       Date:  2019-11-08       Impact factor: 4.790

6.  Is concern for gynaecological alarm symptoms associated with healthcare-seeking? A Danish population-based cross-sectional study.

Authors:  Anja Schmidt Vejlgaard; Sanne Rasmussen; Peter Fentz Haastrup; Dorte Ejg Jarbøl; Kirubakaran Balasubramaniam
Journal:  BMC Public Health       Date:  2022-01-06       Impact factor: 3.295

7.  Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.

Authors:  Karl-Ulrich Petry; Kaatje Bollaerts; Paolo Bonanni; Margaret Stanley; Rosybel Drury; Elmar Joura; Susanne K Kjaer; Chris J L M Meijer; Didier Riethmuller; Benoit Soubeyrand; Pierre Van Damme; Xavier Bosch
Journal:  Hum Vaccin Immunother       Date:  2018-05-24       Impact factor: 3.452

Review 8.  A comparative analysis of cervical cancer prevention between Nigeria and Nordic countries that have experienced a decline in cervical cancer incidence.

Authors:  Helen I Anyasi; Anna M Foss
Journal:  Int Health       Date:  2021-07-03       Impact factor: 2.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.